Clinical Trials

Searchable database of currently enrolling clinical trials
From the Editor

From the Desk of Evan Yu: “The Next Step in Bladder Cancer Immune-Oncology Therapy? Combination Therapy!”

Evan Y. Yu
April 17, 2019

Back in May 2017, I wrote an article for this column in response to the press release that atezolizumab did not offer a survival benefit over taxane chemotherapy in the IMvigor 211 randomized, phase 3 trial, for patients in the post-platinum locally-advanced or metastatic urothelial carcinoma setting.1  At the time, we didn’t understand what had happened to lead to this negative result, especially since the phase 12 and 23 atezolizumab data had been so promising.  Additionally, we had just seen survival benefit with pembrolizumab in the same clinical disease state.4  Eventually, we learned the problem…clinical trial design. 

READ MORE PREVIOUS ARTICLES

Dr. Evan Yu, MD

Evan Yu, MD

Evan Yu, a medical oncologist, treats prostate, bladder and testicular cancer, and is passionate about providing a personalized medical approach to a selection of novel therapies as well as understanding biologic mechanism of drug sensitivity and resistance.

Clinical Expertise

Medical Oncology, Translational Research, Novel molecular targeted agents, Biomarkers, Imaging (PET scans, MRI), Bone health.

  • Professor, Department of Medical Oncology, University of Washington School of Medicine
  • Member, Fred Hutchinson Cancer Research Center
  • Assistant Fellowship Director, Hematology and Oncology Fellowship Training Program, University of Washington and Fred Hutchinson Cancer Research Center.
Search Clinical Trials by Disease

Disclaimer: We update this information regularly. However, what you read today may not be completely up to date. Please remember: Talk to your health care providers first before making decisions about your health care. Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.

E-Newsletters

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.

Subscribe